HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat ...

∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. IARS2, isoleucyl-tRNA synthetase 2; PDAC, pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of ...

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive tract diseases, positioning these molecules as potential biomarkers for ...

Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...

Their findings revealed that these genes play a role in male fertility and in generating small RNA molecules in mature sperm known as tRNA fragments (tRFs). tRFs are created by cleavage of transfer ...

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Clinical-stage biotech company aTyr Pharma (ATYR) has seen a significant 24% increase in stock value over the past week, as the company posted ...